Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13881955 | 0.91 | PPARG (0.43) | PNMTPPARGSLC22A12MAPTSMN1; SMN2 | |
| SCHEMBL3962645 | 0.84 | PPARG (0.48) | PNMTPPARGSLC22A12MAPTSMN1; SMN2 | |
| SCHEMBL27690525 | 0.81 | PNMT (0.49) | PNMTMAPTSMN1; SMN2GAAALOX12 | |
| SCHEMBL13881871 | 0.80 | POLB (0.47) | PNMTPPARGSLC22A12MAPTSMN1; SMN2 | |
| SCHEMBL16348356 | 0.78 | TSPO (0.50) | PPARGSLC22A12MRGPRX4 | |
| SCHEMBL31053230 | 0.78 | PPARG (0.58) | PPARGSLC22A12SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL20592695 | 0.77 | THRB (0.48) | PNMTMAPTSMN1; SMN2GAAALOX12 | |
| SCHEMBL1043810 | 0.77 | CES2 (0.49) | PNMTMAPTSMN1; SMN2GAAALOX12 | |
| SCHEMBL30836057 | 0.77 | CES2 (0.49) | PNMTMAPTSMN1; SMN2GAAALOX12 | |
| SCHEMBL13522825 | 0.77 | P2RY14 (0.41) | MAPTALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | claimed |
| WO-2009046371-A1 | METHODS OF TREATING METABOLIC DISEASES | METABOLEX, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1716116-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080340-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | GPR119, SLC5A1, AADAC | PNMT 774/4885PPARG 16/4885SLC22A12 554/4885 |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | SLC5A1, GPR119, SLC5A2 | PNMT 747/4885PPARG 19/4885SLC22A12 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.